Catalyst Calendar

PDUFA dates and AdCom meetings, tightly curated.

Upcoming FDA decisions for the most-watched names. We deliberately keep the list focused on dates that move stocks meaningfully — for full pipeline coverage, paid services like BiopharmCatalyst go deeper.

Loading calendar…

What is a PDUFA date?

The Prescription Drug User Fee Act sets the deadline by which the FDA must complete its review of a New Drug Application. When a company submits a drug for approval, FDA assigns a PDUFA date — typically 6 months out for priority review or 10 months for standard review. The agency either approves, issues a Complete Response Letter (effectively a denial with feedback), or extends the date.

Stocks routinely move 20–60% on PDUFA outcomes. The dates are knowable in advance because companies disclose them in 10-Q filings and press releases.

What is an AdCom?

Advisory Committee meetings. FDA convenes external panels of clinicians and statisticians to review controversial or first-in-class drug applications. The committee votes on safety and efficacy questions, and FDA usually (though not always) follows the recommendation. AdCom days regularly produce 30%+ stock moves on the underlying.

Not all drug applications go through AdCom — only ~10% do, typically when there's clinical controversy or a novel mechanism.

Sourcing

Manually curated from company 10-Q filings, press releases, and FDA briefing documents. We focus on the 20–30 most-watched names where a date can move the stock by 10%+. Entries older than one week are auto-filtered out. The list updates whenever new dates surface.

The FDA does not publish a clean machine-readable PDUFA calendar. AdCom dates are public on FDA.gov; that auto-scrape is in the v1.4 backlog.

How to use this

Dates are best-known estimates and can be extended, withdrawn, or accelerated by FDA without notice. Always verify with the company's most recent SEC filings before trading.

Healthcare.feargreedchart.com provides healthcare-sector sentiment data and historical statistics for informational and educational purposes only. Nothing on this site constitutes financial advice or a solicitation to buy or sell securities. Past patterns are not predictive of future results.